MA-PRESS-GANEY/FORSTA
27.4.2022 15:02:07 CEST | Business Wire | Press release
Press Ganey , renowned leader in patient, member, employee and consumer experience across the healthcare ecosystem, announced it has completed its acquisition of Forsta , a leading global provider of market research, customer experience (CX) and employee experience (EX) technology. The closing is effective as of April 26, 2022.
As industry-recognized leaders, with Press Ganey recently selected Best in KLAS for Patient Experience Improvement and Forsta named a Leader in the 2021 Gartner® Magic Quadrant™ for Voice of the Customer , the combined companies will power the future of research and experience technology.
“Together, Press Ganey and Forsta offer our clients the data connectivity, accelerated analytics, DEI expertise and deeply segmented insights that companies need to deliver frictionless experiences and truly drive transformation,” said Patrick T. Ryan, chairman and chief executive officer, Press Ganey. “With Forsta, we expand into new geographies and industries, with highly complementary market research, CX and EX technology that will coordinate seamlessly with our existing healthcare solutions.”
“Press Ganey is expediting Forsta’s mission to reinvent the global insights industry. With this investment, we will be able to greatly accelerate innovation so our customers can deliver better insights, faster and at scale,” said Kyle Ferguson, chief executive officer, Forsta. “There is tremendous opportunity from the convergence of our resources, and we have no plans to slow down.”
Acquisition Highlights
Fast-tracked Product Innovation. Press Ganey’s investment will advance Forsta’s product innovation at an accelerated pace, especially in the high-demand areas of artificial intelligence (AI), data visualization and qualitative research.
Marketplace Expansion. Forsta’s global presence and extensive network will propel Press Ganey’s international healthcare growth ambitions while also expanding the company into new verticals, such as retail, financial services and consumer goods.
Unparalleled Insights. Both companies are proven changemakers and bring proprietary research and thought leadership to deliver key insights that tackle essential issues, like barriers to human-centered data , employee burnout and advancing health equity .
Healthcare Sector Disruption. Backed by blue-chip consulting, unparalleled experience measurement expertise and proprietary analytics to help drive improvement, Press Ganey will offer breakthrough advancements to the evolving healthcare marketplace. A new suite of purpose-built for healthcare, self-service solutions are immediately available, like digital communities, virtual focus groups, crowdsourcing and more.
Exceptional Human Capital. Two empowered, elite workforces will come together around aligned missions and pursuits to seamlessly turn data into meaningful insights that drive impact.
The joint company will continue to be led by Ryan as chairman and CEO, and Ferguson will remain at the helm of Forsta as CEO. Combined, the organization’s 3,000+ employees now serve thousands of customers, including Fortune 500 companies and top healthcare systems, throughout the North America, EMEA (Europe-Middle East-Africa) and APAC (Asia-Pacific) regions.
About Press Ganey
Press Ganey invented the healthcare performance improvement movement over 35 years ago. Today it offers an integrated suite of solutions that address safety, clinical excellence, patient experience and workforce engagement. The company works with more than 41,000 healthcare facilities in its mission to reduce patient suffering and enhance caregiver resilience to improve the overall safety, quality and experience of care.
About Forsta
Forsta powers an Experience and Research Technology Platform that gathers and analyzes data, and translates the findings into shareable actions to inform decision-making and drive growth. Forsta’s technology, combined with its team of expert consultants, help organizations better understand the full Human Experiences (HX) of their audiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005008/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom